logo
welcome
Reuters

Reuters

Novavax cuts 2024 revenue forecast on lower COVID vaccine sales

Reuters
Summary
Nutrition label

81% Informative

Shares of the company were down 14% in premarket trading.

The vaccine maker now expects $275 million to $375 million in product sales for the year .

Novavax has struggled to sell its protein-based COVID vaccines and failed to make a significant dent in the market share of key players.

VR Score

92

Informative language

98

Neutral language

81

Article tone

semi-formal

Language

English

Language complexity

47

Offensive language

not offensive

Hate speech

not hateful

Attention-grabbing headline

not detected

Known propaganda techniques

not detected

Time-value

short-lived

External references

no external sources

Source diversity

no sources

Affiliate links

no affiliate links